Playing The Biotech Breakout With Insiders
Alpha Cognition Inc ACOG
$8.28
▼ -5.15%
($-0.45)
🎢 High Beta
🗓️ Earnings Next Week
Open
$8.56
Prev Close
$8.73
Day Range
$7.54 – $8.72
52W Range
$4.50 – $10.15
Market Cap
$180.29M
Beta
8.66
EPS (TTM)
$-1.34
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-09 |
| Shares Out. | 21,770,000 |
| Website | alphacognition.com/ ↗ |
| Phone | 16045649244 |
| Employees | 71 |
| Revenue | $3.5M |
| Gross Profit | $3.3M |
| Net Income | -$6.5M |
| Free Cash Flow | -$30.4M |
| Total Assets | $69.2M |
| Total Liabilities | $11.8M |
| Equity | $57.5M |
About Alpha Cognition Inc
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Alpha Cognition Inc is a publicly traded company under the ticker symbol ACOG on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)